# Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia

> **NCT00270478** · PHASE1 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 7 (actual)

## Conditions studied

- Sickle Cell Disease
- Chronic Kidney Disease
- Pulmonary Hypertension

## Interventions

- **DRUG:** Erythropoietin and Hydroxyurea

## Key facts

- **NCT ID:** NCT00270478
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12-21
- **Primary completion:** 2009-08-31
- **Final completion:** 2009-08-31
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00270478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00270478, "Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00270478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*